A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a by Roberts, Jacob T. & Barb, Adam W.
Biochemistry, Biophysics and Molecular Biology
Publications Biochemistry, Biophysics and Molecular Biology
12-21-2018
A single amino acid distorts the Fc γ receptor IIIb/
CD16b structure upon binding immunoglobulin
G1 and reduces affinity relative to CD16a
Jacob T. Roberts
Iowa State University, jtr@iastate.edu
Adam W. Barb
Iowa State University, abarb@iastate.edu
Follow this and additional works at: https://lib.dr.iastate.edu/bbmb_ag_pubs
Part of the Biochemistry Commons, Biophysics Commons, Molecular Biology Commons, and
the Structural Biology Commons
The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/
bbmb_ag_pubs/210. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Biochemistry, Biophysics and Molecular Biology at Iowa State University Digital
Repository. It has been accepted for inclusion in Biochemistry, Biophysics and Molecular Biology Publications by an authorized administrator of Iowa
State University Digital Repository. For more information, please contact digirep@iastate.edu.
A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon
binding immunoglobulin G1 and reduces affinity relative to CD16a
Abstract
Therapeutic mAbs engage Fc γ receptor III (CD16) to elicit a protective cell-mediated response and destroy
the target tissue. Newer drugs designed to bind CD16a with increased affinity surprisingly also elicit
protective CD16b-mediated responses. However, it is unclear why IgG binds CD16a with more than 10-fold
higher affinity than CD16b even though these receptors share more than 97% identity. Here we identified one
residue, Gly-129, that contributes to the greater IgG binding affinity of CD16a. The CD16b variant D129G
bound IgG1 Fc with 2-fold higher affinity than CD16a and with 90-fold higher affinity than the WT.
Conversely, the binding affinity of CD16a-G129D was decreased 128-fold relative to WT CD16a and
comparably to that of WT CD16b. The interaction of IgG1 Fc with CD16a, but not with CD16b, is known to
be sensitive to the composition of the asparagine-linked carbohydrates (N-glycans) attached to the receptor.
CD16a and CD16b-D129G displaying minimally processed oligomannose N-glycans bound to IgG1 Fc with
about 5.2-fold increased affinity compared with variants with highly processed complex-type N-glycans.
CD16b and the CD16a-G129D variant exhibited a smaller 1.9-fold affinity increase with oligomannose N-
glycans. A model of glycosylated CD16b bound to IgG1 Fc determined to 2.2 Å resolution combined with a
250-ns all-atom molecular dynamics simulation showed that the larger Asp-129 residue deformed the Fc-
binding surface. These results reveal how Asp-129 in CD16b affects its binding affinity for IgG1 Fc and
suggest that antibodies engineered to engage CD16b with high affinity must accommodate the Asp-129 side
chain.
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Therapeutic mAbs engage Fc  receptor III (CD16) to elicit a
protective cell-mediated response and destroy the target tissue.
Newer drugs designed to bind CD16a with increased affinity
surprisingly also elicit protective CD16b-mediated responses.
However, it is unclear why IgG binds CD16a with more than
10-fold higher affinity than CD16b even though these receptors
share more than 97% identity. Here we identified one residue,
Gly-129, that contributes to the greater IgG binding affinity of
CD16a. The CD16b variant D129G bound IgG1 Fc with 2-fold
higher affinity than CD16a andwith 90-fold higher affinity than
the WT. Conversely, the binding affinity of CD16a-G129D was
decreased 128-fold relative to WT CD16a and comparably to
that ofWT CD16b. The interaction of IgG1 Fc with CD16a, but
not with CD16b, is known to be sensitive to the composition of
the asparagine-linked carbohydrates (N-glycans) attached to the
receptor. CD16a and CD16b-D129G displaying minimally pro-
cessed oligomannose N-glycans bound to IgG1 Fc with about
5.2-fold increased affinity compared with variants with highly
processed complex-type N-glycans. CD16b and the CD16a-
G129Dvariant exhibited a smaller 1.9-fold affinity increasewith
oligomannoseN-glycans.Amodel of glycosylatedCD16bbound
to IgG1 Fc determined to 2.2 Å resolution combined with a
250-ns all-atom molecular dynamics simulation showed that
the larger Asp-129 residue deformed the Fc-binding surface.
These results reveal how Asp-129 in CD16b affects its binding
affinity for IgG1 Fc and suggest that antibodies engineered to
engage CD16b with high affinity must accommodate the Asp-
129 side chain.
IgG opsonizes a previously encountered pathogen to target it
for destruction by eliciting an immune response. IgG binds the
target with high specificity through antigen binding fragments
(Fabs) and interacts with innate immune system effector cells
through the crystallizable fragment (Fc) by engaging Fc recep-
tors (FcRs), thus bridging the adaptive and innate immune
systems (Fig. 1). There are three classes of cognate human
FcRs: FcRI (CD64), FcRII (CD32), and FcRIII (CD16) (1).
CD16 is of particular interest because it is the primary receptor
responsible for antibody-dependent cell-mediated cytotoxicity
and, thus, tumor clearance (2, 3). Two CD16 forms, CD16a and
CD16b, bind to IgG1 with surprisingly different affinities con-
sidering the high degree of structural and sequence similarity
(4, 5). In this manuscript, we probe the contribution of an
amino acid residue to the different binding affinities of CD16a
and CD16b.
CD16a is an integral membrane protein predominantly
expressed on NK2 cells and monocytes. CD16b is predomi-
nantly expressedwith a glycosylphosphatidylinositol anchor on
neutrophils, a subset of basophils and shows inducible expres-
sion on eosinophils (6–12) (Fig. 1). CD16a has two predomi-
nant alleles (V158 or F158) and CD16b has two predominant
alleles, including human neutrophil antigen 1 (HNA-1 or NA1)
and NA2 (13, 14). CD16a-V158 and CD16b-NA2 share 97%
sequence identity and differ by only four amino acid residues in
the extracellular antibody-binding domains (Fig. 1B). Despite
the significant homology shared by CD16a and CD16b, CD16a
binds antibodies more than 10-fold tighter, although it is
unclear how differences in these four amino acids contribute to
differences in binding affinity (5). Only one of these four differ-
ences, at position 129, forms part of the IgG1-binding interface.
FcRs are heavily modified with asparagine-linked carbohy-
drates (N-glycans; for a review of N-glycosylation, see Ref. 15).
CD16a has as many as fiveN-glycans, and CD16b (NA2) has as
many as six, although it is not clear whether all sites are fully
occupied. The N-glycan composition of CD16 appears to be
varied, depending on the type of expressing cell, and it has been
shown that different cells bind IgG with different affinity
through CD16 (16–19). Three recent studies reported that the
binding affinity of CD16a is influenced by receptor N-glycan
composition (19–21). In one example, CD16a with minimally
This work was supported by NIGMS, National Institutes of Health under
Award R01 GM115489, the Roy J. Carver Department of Biochemistry, Bio-
physics, andMolecular Biology at Iowa StateUniversity, andby theDepart-
ment of Energy for synchrotron time at the Argonne National Laboratory
AdvancedPhoton Source (GUP-48455). The authors declare that they have
no conflicts of interestwith the contents of this article. The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. Any opinions, findings,
and conclusions or recommendations expressed in this material are those
of the authors and do not necessarily reflect the views of the Department
of Energy.
This article contains Figs. S1–S3 and Table S1.
Theatomiccoordinatesandstructure factors (code6EAQ)havebeendeposited in
the Protein Data Bank (http://wwpdb.org/).
1 To whom correspondence should be addressed: Roy J. Carver Dept. of Bio-
chemistry, Biophysics, and Molecular Biology, 4210 Molecular Biology
Bldg., Iowa State University, Ames, IA 50011. Tel.: 515-294-8928; E-mail:
abarb@iastate.edu.
2 The abbreviations used are: NK, natural killer; MD, molecular dynamics; CT,
complex-type;HILIC, hydrophilic interaction chromatography; ESI, electro-
spray ionization.
croARTICLE
J. Biol. Chem. (2018) 293(51) 19899–19908 19899
© 2018 Roberts and Barb. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
 at IO
W
A
 STA
TE U
N
IV
 on February 18, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
processed Man5 N-glycans bound 12-fold tighter to IgG1 Fc
(G0F) than CD16a, with highly processed and elaborated com-
plex-type N-glycans, but glycan composition only impacted
CD16b affinity by less than 2-fold (examples of differentN-gly-
coforms are shown in Fig. 2) (19, 22). This result is surprising
considering the significant homology shared by CD16a and
CD16b (Fig. 1 and Fig. S1). TheCD16aN-glycan at position 162
mediated this effect, which, likewise, may be influenced by the
nearby Gly-129 residue (20).
The N-glycan composition of the IgG1 Fc is a well-known
variable in CD16 binding affinity (3, 23–26). This property
directly impacts the development of therapeutic mAbs because
increasing affinity for CD16 increased therapeutic efficacy (13,
25, 27–29). A major advance for mAb development occurred
with the observation that IgG lacking a prevalent antibody
modification, l-fucose attached to the core (1)GlcNAc residue
of theN-glycan, increased binding affinity and antibody-depen-
dent cell-mediated cytotoxicity (30). This observation inspired
the development of many new glycoengineered mAb therapies
(31–34). Notably, CD16b demonstrated a larger enhancement
in binding nonfucosylated IgG1 Fc in vitro compared with
CD16a in vitro (5). The current generation of glycoengineered
antibodies ismore effective at binding toCD16b on neutrophils
and eliciting effector responses, showing greater therapeutic
potential (35, 36). These studies support the development of
mAbs that bindCD16bwith higher affinity tomobilize an effec-
tive neutrophil response. However, the development of future
mAbs is limited by a lack of information regarding the detailed
mechanism and identification of which residues contribute to
the reduced affinity of CD16b for IgG1 Fc compared with
CD16a.
A comparison of the amino acid sequences for CD16b and
CD16a reveals that only one of the four differences in the anti-
body-binding domains, at position 129, directly contributes the
interface formed with IgG1 Fc (Fig. 1B). If Asp-129 of CD16b
disrupts this interface, then CD16b D129G is expected to bind
as tightly as CD16a, andCD16aG129Dwill bindwith less affin-
ity. Furthermore, if CD16a Gly-129 contributes to the sensitiv-
ity of affinity to receptor N-glycan composition, then CD16a
G129D should no longer be sensitive toN-glycan composition.
Figure 1. FcR III/CD16 is expressed in two forms from twodistinct genes.A and B, FcRIIIb/CD16b is highly expressed onneutrophils, and FcRIIIa/CD16a
is the predominant FcR expressed on NK cells. B, these proteins differ by only four amino acid residues (highlighted in yellow) in the mature proteins. The
N-terminal signal peptide is indicated in redand isnot found in the fullyprocessedproteins. TheC-terminal residuesofCD16bshown inorangeare cleavedprior
to addition of the glycosylphosphatidylinositol anchor at the newly uncovered C-terminal serine. N-glycosylation sites are indicated with gray shading. Both
proteins are cleaved by ADAM17 and released from the cell surface following cell activation. Resolved N-glycan residues are shown as spheres.
CD16b Asp-129 decreases affinity for IgG1
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In this manuscript, we evaluate how Gly-129 and Asp-129
impact the affinity of CD16 for IgG1 Fc. We also determined
how these residues modulate the differential sensitivity of
CD16a and CD16b to N-glycan composition.
Results
N-glycomics of the recombinant proteins
To evaluate the impact of N-glycan composition and Asp-
129 versusGly-129 on CD16 structure and IgG1 Fc binding, we
expressed four CD16 variants, including CD16a, CD16a
G129D, CD16b, and CD16b D129G, using two cells lines that
resulted in a panel of eight receptor variants. One cell line,
HEK293F, contains a large repertoire of glycan-modifying en-
zymes and expressed CD16 with a heterogeneous mixture of
highly branched complex-type N-glycans (Fig. 2 and Fig. S2).
The second cell line, HEK293S, contains a defect in the GNT1
gene (37, 38) and expressed CD16 with predominantly Man5
oligomannose-type N-glycans, although small amounts of
Man6, Man7, Man8, and Man9 were also present (Fig. 2).
rCD16b D129G-CT binds IgG1 Fc with an affinity comparable
with rCD16a-CT
WT recombinant (r)CD16a-CT bound IgG1 Fc glycoforms
with affinities between 38- and 60-fold tighter than rCD16b
(Fig. 3 and Table 1). These values were comparable with previ-
ous results from our laboratory; however, the binding of
rCD16a-CT is roughly 1.5 to 4-fold tighter (5, 20). As predicted,
rCD16a-CT bound IgG1 Fc with more than 100-fold greater
affinity than rCD16a G129D-CT. The rCD16a G129D-CT var-
iant bound with an affinity comparable with rCD16b-CT (22
mM versus 6.4 mM, respectively; Fig. 4). In the complementary
experiment, rCD16b-D129G-CT bound at least 64-fold tighter
to three IgG1 FcN-glycoforms than rCD16b-CT. Furthermore,
the affinities of rCD16a-CT and rCD16b D129G-CT were less
than 3.1-fold different, confirming the importance of a Gly at
position 129 in high-affinity IgG1 Fc binding. It is possible that
subtle differences in N-glycan composition resulting from
expression conditions, in particular the N-glycan at Asn-162,
impact the measured affinity. This effect is noted for CD16b
D129G-CT, which contains a larger amount of oligomannose
N-glycans compared with CD16a (Fig. S2).
Tighter-binding CD16 variants are sensitive to N-glycan
composition
Comparing the binding affinities of the CD16 variants with
differentN-glycan composition provided insight into the role of
Gly-129 in the higher-affinity interactions. All receptor variants
bound tighter with oligomannose N-glycans; however, recep-
tors with a Gly residue at position 129 showed an average affin-
ity increase of 5.2 2.6-fold compared with 1.9 0.8-fold for
receptors with an Asp residue at position 129 (Table 1).
The CD16 129 residue impacts association and dissociation of
IgG1 Fc
The receptor variants that boundwith lower affinity revealed
very fast apparent association and dissociation kinetics using
the relatively high concentrations of analytes required to reach
saturation (CD16b and CD16a G129D). These rates were too
rapid to accurately estimate from the surface plasmon reso-
nance sensorgrams because binding was limited by the rate of
analyte flow over the chip surface (Fig. 3). Conversely, variants
that bound with higher affinity showed slower observed associ-
ation and dissociation rates (CD16a andCD16bD129G). These
observed rates appeared to be slow because of the small
amounts of receptor used for the binding measurements and
are not comparable with the association rates measured for the
low-affinity variants that were tested at much higher analyte
concentrations and likely bind with equal or slower on rates. As
a result, the associations for the high-affinity variants failed to
reach equilibrium after 800 s, and only an analysis of binding
kinetics provided appropriate estimates of KD (Fig. 3 and Table
2). Reactions that permitted KDmeasurement using both equi-
librium and kinetic data revealed comparable results and vali-
dated the direct comparison of KD values measured from both
types of data (Tables 1 and 2).
Among the high-affinity variants, it is notable that
rCD16a-CT bound to IgG1 Fc G0F and G0 with the slowest of
the measured on rates (39 and 98mM1 s1, respectively, com-
Figure2. Total ioncurrentofprocainamide-derivedCD16bN-glycansexpressed in twodistinctglycoformsandanalyzedbyHILIC-MS.Top, CD16bwas
expressed to display Man5 N-glycans. Bottom, CD16b with CT N-glycans.
CD16b Asp-129 decreases affinity for IgG1
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pared with 306–685mM1 s1; Table 2). Surprisingly, rCD16b
D129G bound with a 3- to 8-fold faster kON compared with
rCD16a but more similar kOFF values (0.8 to 3.7-fold differ-
ence). These differences contribute to KD values that were no
more than 2.1 to 2.3-fold different. This result indicates that
substitution at residue 129 does not transfer the complete
kinetic properties between CD16a and CD16b.
The structure of glycosylated CD16b in complex with IgG1 Fc
Three models of IgG1 Fc bound to nonglycosylated CD16b
revealed the structural features of low-affinity FcRs bound to
antibody (39, 40). However, the availability of moderate resolu-
tion diffraction (3.0–3.5 Å), moderate Rfree values (0.28–0.36),
and high temperature factors for the Asp-129 backbone atoms
(78–104Å2) limit the ability to formulate hypotheses regarding
Figure 3. The binding affinity and binding kinetics of the CD16b D129G protein are comparable with the high-affinity CD16a protein. Shown are
representative binding sensorgrams for the CD16 variants binding to IgG1 Fc (G0 glycoform). Dissociation constants were determined using equilibrium
intensity values, with the exception of KD values marked with an asterisk, which were calculated by fitting kinetic data. Errors indicate uncertainties from the
curve fitting procedures.
CD16b Asp-129 decreases affinity for IgG1
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the position of individual atoms at the Fc–receptor interface
and compare with three higher quality structures of the CD16a:
IgG1 Fc complex (2.2 Å with Rfree values of 0.24–0.26 (20, 41,
42)). One feature of the higher-quality CD16a complexes is the
presence of the Asn-45 and Asn-162 glycans. Multiple reports
highlight the importance of these two N-glycans and the dis-
pensability of the remaining threeN-glycans to IgG1 Fc binding
affinity (20, 43, 44). To improve the crystal quality, we prepared
glycosylated rCD16b-Man5with four of the sixN-glycosylation
sites removed by mutating the modified Asn residue to a Gln
(N38Q/N64Q/N74Q/N169Q). Indeed, this rCD16b-Man5 var-
iant bound IgG1 Fc with 0.7- to 0.9-fold of the affinity observed
using rCD16b-Man5 and indicated suitability for crystalliza-
tion trials (Table 1).
Two crystal forms of the rCD16b-Man5–IgG1 Fc complex
diffracted to high resolution. One form crystallized in the
P212121 space group and diffracted to 2.5 Å (data not shown). A
second crystal in the C2 space group diffracted to 2.22 Å with
high completeness (Table S1). The CD16a–IgG1 Fc complex
provided initial phases (20), and the iterative refinement of the
higher-resolution data resulted in an Rfree of 0.2477 as well as a
model with no Ramachandran outliers and only 1.2% of side
chain rotamer outliers. As expected, the overall structure is
highly similar to other CD16a and CD16b models (Fig. 5). This
structural model has a root mean square deviation of 0.499 Å
compared with the rCD16a-Man5–IgG1 Fc complex (PDB
code 5VU0 (20)) and 2.054 Å compared with a nonglycosylated
rCD16b–IgG1 Fc complex (PDB code 1T89 (40)).
The Asp-129 residue of CD16b distorts the Fc-binding interface
In addition to higher-resolution data and higher refinement
scores compared with previous CD16b–IgG1 Fc complexes,
themodel calculated from the 2.22Å dataset provided low tem-
perature factors for the interface residues with values for the
Asp-129 backbone atoms ranging from 42 to 43 Å2 (compared
with 78–104 Å2 for previous CD16b models). These lower val-
ues allow comparison with CD16a models with similar quality
(Fig. 5C). Despite the high degree of amino acid similarity, the
interface formed between CD16b and IgG1 Fc is smaller and
involves less residues than the interface formed by CD16a (Fig.
S3). The buried surface areameasuredwith thismodel is 860Å2
and comparable with previous CD16bmodels (PDB code 1T89,
737 Å2; PDB code 1E4K, 816 Å2 (39, 40)). These areas are less
than those measured with the CD16a–IgG1 Fc complex (PDB
code 3SGJ, 1193 Å2; PDB code 3AY4, 924 Å2; PDB code 5VU0,
897 Å2 (20, 41, 42)).
Asp-129 represents the only amino acid difference between
CD16b and CD16a that is found at the interface formed with
IgG1Fc. The close approach of theCD16aGly-129 amide nitro-
gen to the IgG1 Fc Tyr-296 carbonyl (3.2 Å) is prevented by the
CD16b Asp-129 residue, increasing this internuclear distance
to 4.5 Å and distorting the CD16b backbone (Fig. 5, D and E).
Surprisingly, it appears that this distortion is not present in the
absence of IgG1 Fc; a model of unliganded CD16b reveals a
backbone conformation identical to CD16a in the region of
Asp-129 (Fig. 6A). The observed conformation in the unligan-
ded CD16bmodel places the Asp-129 side chain within the van
der Waals radii of the IgG1 Fc Asn-297 residue. Thus, CD16b
must deform to accommodate IgG1 Fc, distorting the back-
bone. These changes at the Fc interface potentially explain why
CD16b binds IgG1 Fc weaker than CD16a.
The backbone distortion because of Asp-129 impacts the
local tertiary structure, deforming the  sheet and reducing the
distance across the sheet by 1.2 Å compared with CD16a (as
measured by the distance to Arg-155; Fig. 6, A and B). This
change impacts the conformation of the Arg-155 side chain,
which forms an interface with the Asn 162 glycan (1)GlcNAc
residue in the CD16a complex. In the CD16b complex, the con-
tacts between Arg-155 and the (1)GlcNAc residue are reduced
as the Arg-155 side chain shifts away from the carbohydrate
(Fig. 6,C–F). This intramolecular interface formed between the
Asn-162 glycan (1)GlcNAc residue and the Arg-155 side chain
may explainwhy the affinity of IgG1 for CD16a, but not CD16b,
is sensitive to the receptor N-glycan composition (Fig. 4 and
Table 1).
MD simulations of the CD16b–IgG1 Fc complex
Measurements of binding affinity pinpointed the residue at
position 129 as a critical difference betweenCD16a andCD16b.
X-ray crystallography highlighted differences in the interfaces
formed by these receptors and IgG1 Fc. However, these data
represent a single conformational snapshot, and it remained
unclear whether X-ray crystallography only captured a repre-
sentative state. The N-glycosylated CD16b–IgG1 Fc complex
served as a starting point for a 250-ns all-atom molecular
dynamics simulation to compare with a recent 250-ns simula-
Table 1
Binding affinity measurements with two receptor glycoforms and
three IgG1 Fc glycoforms determined by surface plasmon resonance
Receptor
IgG1 Fc G0F IgG1 Fc G2F IgG1 Fc G0
KD
(nM)

error
KD
(nM)

error
KD
(nM)

error
rCD16a-CT 10 70 2 25 1
rCD16a G129D-CT 22,000 1,000 12,500 600 3,000 200
rCD16b-CT 6,400 400 4,200 300 950 100
rCD16b D129G-CT 100 10 48 3 8 1
rCD16a-Man5 48 2 22 1 3.9a 1.0
rCD16a G129D-Man5 9,500 300 4,000 200 1,100 100
rCD16b-Man5 5,200 300 2,900 200 560 30
rCD16b D129G-Man5 13 1 6.0 0.3 3.6a 1.0
rCD16b
N38Q/N64Q/N74Q/
N169Q-Man5
6,400 600 4,000 400 650 50
a KD values were calculated from kinetic data.
Figure 4. A glycine at position 129 of CD16 is essential for high-affinity
IgG1 Fc binding. Dissociation constants indicate the impact of the IgG1 Fc
N-glycan, CD16 in N-glycan, and the residue at position 129 on binding affin-
ity. Error bars indicate the error of fit for the interactions.
CD16b Asp-129 decreases affinity for IgG1
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tion of theCD16a–IgG1 Fc complex to assess the stability of the
observed interactions on this timescale (20). Although this sim-
ulation timescale is insufficient to probe all potential conforma-
tions accessed by these proteins, it may prove to be informative
regarding differences in local conformation potentially gov-
erned by low energetic barriers that would be sampled in a
relatively restricted simulation.
Distances separating the CD16 129 residue and the IgG1 Fc
C’E loop showed values consistent with themodels determined
by X-ray crystallography: the CD16b Gly-129 C atom was 4.6
Å from the Fc Asn-297 C compared with 3.9 Å for the CD16a
complex (Fig. 6). Although the average distances observed with
MD are slightly larger (5.0 and 4.3 Å, respectively), the differ-
ences of 0.7 Å are identical (Fig. 7). These greater distances for
CD16b separated the CD16a Gly-129 N and Fc Tyr-296 O
atoms (average, 4.8 Å), which participated in an H-bond in the
CD16a simulations (average, 3.0 Å). In the CD16b simulations
and model determined by X-ray crystallography, this H-bond
was replaced by an interaction with the CD16b Lys-128 Nz
atom, which sampled distances within H-bond range in the
CD16b simulation but not in the CD16a simulation (Fig. 7, bot-
tom panels).
Simulation likewise preserved the observed deformation of
the CD16b  sheet induced by Asp-129 that reduced the dis-
tance between the Arg-155 and 129 C atoms by 1.2 Å com-
pared with CD16a (Fig. 6, A and B). Although the difference in
averages is somewhat smaller in the simulations at 0.8 Å, the
same trend is observed until the very end of the CD16b simu-
lation (Fig. 7). Interestingly, CD16b drifts slightly away from
IgG1 Fc in the final 30 ns of the simulation, as indicated by the
increasing distances between CD16b Asp-129 and Fc residues
Asn-297 and Tyr-296. At the same time, the  sheet deforma-
tion also disappears, and the distance between the CD16b Arg-
155 and Gly-129 C atoms matches the CD16a simulation (9.6
Table 2
Association and dissociation rate constants measured from kinetic fits of the surface plasmon resonance sensorgrams
Receptor
IgG1 Fc G0F IgG1 Fc G0
kON (mM1s1)  error kOFF (s1)  error KD (nM) kON (mM1s1)  error kOFF (s1)  error KD (nM)
rCD16a-CT 39 11% 0.00506 14% 130 98 13% 0.00420 10% 43
rCD16b D129G-CT 306 18% 0.01853 16% 61 317 4% 0.00323 10% 100
rCD16a-Man5 437 19% 0.01729 16% 40 625 1% 0.00242 29% 3.9
rCD16b D129G-Man5 422 2% 0.00440 18% 10 685 4% 0.00246 20% 3.6
Figure 5. CD16a binds IgG1 Fc with greater affinity and makes a closer
approachto IgG1Fc throughthe loopcontainingresidue129.AandB, the
overall complexes formedbyCD16a (A) andCD16b (B) with IgG1 Fc are highly
similar with a rootmean square deviation of 0.499 Å. The protein backbone is
shown as ribbons, andN-glycans are shown as sticks.C, the electron density of
the CD16b region surrounding Asp-129 is well-resolved at 1.5 . D and E, the
Gly-129 amide nitrogen atom of CD16a (D) is located 1.3 Å closer to the car-
bonyl carbonof the IgG1FcAsn-297 than theamidenitrogenofAsp-129 from
CD16B (E).
Figure 6. Asp-129 in CD16b decreases the distance between  strands
and distorts the interface formed between the Asn-162-glycan and Arg-
155 comparedwith Gly-129 and CD16a. A, the CD16a complex with glyco-
sylatedCD16a is shown in red (PDB code5VU0 (20)) and superimposedon the
unliganded (unlig.) CD16b (PDB code 1E4J (39)), shown in gray. Note that the
position of the Asp-129 side chain clashes with the IgG1 Fc C’E loop. B, glyco-
sylatedCD16b in complexwith IgG1 Fc is shown in orange and superimposed
on the unliganded CD16b, shown in gray. IgG1 Fc binding distorts the con-
formation surrounding Asp-129, shortening the distance from Asp-129 to
Arg-155. C and E, two views of CD16a, with the polypeptide surface shown in
gray and relevant residues as red sticks.D and F, two poses of CD16b, with the
polypeptide surface shown ingray and relevant residues asorange sticks. This
Asp-129–mediated strand distortion perturbs the interface formed between
the (1)GlcNAc residue of the CD16 Asn-162 glycan and Arg-155.
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Å). This observation supports the conclusion that complex for-
mation and contact with the IgG1 Fc C’E loop impinges on the
CD16b Asp-129 residue.
Discussion
The data presented here demonstrate that a single amino
acid residue at position 129 accounts for the major differ-
ences in binding affinity, binding kinetics, and sensitivity to
receptor N-glycan composition. The presence of a Gly at
CD16 residue 129 supports high-affinity IgG1 Fc binding,
but an Asp residue, as found in CD16b, reduces affinity.
These data are supported by binding measurements and the
structural model of the N-glycosylated CD16b–IgG1 Fc
complex determined by X-ray crystallography. Extensive all-
atom MD simulations further supported differences in the
CD16–IgG1 Fc models.
The deformation of CD16b because of Asp-129 upon com-
plex formation with IgG1 Fc likely contributes an energetic
penalty that prevents CD16b from binding as tightly as
CD16a. This is evident upon examining a model of unligan-
ded CD16b that showed indistinguishable backbone geome-
try compared with CD16a in complex with IgG1 Fc (Fig. 6).
Furthermore, this deformation reduced the buried surface
area formed in the complex. With these data alone, it is not
possible to quantify the impact of the deformation on IgG1
Fc binding affinity because it is not clear how Asp-129
impacts conformational sampling of unliganded CD16b.
Robinson et al. (46) recently noted evidence for sampled
conformation differences between CD16a and CD16b and
developed a CD16a-selective affimer, AfG3, that binds
between the two extracellular domains to a region with con-
served amino acids in CD16a and CD16b. Although the
authors believe that the selectivity of AfG3 is largely due to
H-bonds formed by CD16a Arg-18 (CD16b NA2 S18),
it is clear that amino acid differences distant from the
Figure 7. Internuclear distances observed in crystallography are maintained during 250 ns all-atom molecular dynamics simulations of the CD16-
IgG1Fccomplexes. Left panels, a 10-frameaverageof eachdistanceover the courseof the simulation.Right panels, histograms reporting thenumberof frames
that correspond to eachdistance.Vertical arrows indicate the distancemeasured from structures determinedbyX-ray crystallography (CD16a-IgG1 FcG0 (PDB
code 5VU0 (20)); CD16b-IgG1 Fc G0, this work). Distances correspond to thosemeasured in Figs. 5 and 6. X129 refers to residue Asp-129 of CD16b and Gly-129
of CD16a.
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IgG1-binding surface of CD16 can impact conformational
sampling.
It is surprising that CD16a is more sensitive to N-glycan
composition than CD16b and that this behavior is influenced
by the residue at position 129. As stated, CD16aN-glycan com-
position affects affinity for binding IgG1 Fc (16, 19, 21). The
data presented here further support the recent observation that
CD16a is the only FcR sensitive to receptor N-glycan compo-
sition (Table 1 and Ref. 22). Furthermore, analysis of the CD16
amino acid variants binding to IgG1 Fc highlights the central
role of CD16a Gly-129 in this unexpected behavior. The struc-
ture of glycosylated CD16b in complex with IgG1 Fc provides
some insight into themechanismunderlying this phenomenon:
Asp-129 deforms the CD16b  sheet adjacent to the interface
formed with IgG1 Fc, and this distortion perturbs contacts
between theAsn-162 glycan andArg-155 (Fig. 6). Although it is
unclear why CD16a withMan5N-glycans binds tighter to IgG1
Fc than CD16a with complex-type N-glycans, the ability to
increase the sensitivity of CD16b to N-glycan composition by
the D129G substitution indicates that residues surrounding
Gly-129 are likely involved in this phenomenon.
CD16b has received much less attention than CD16a.
Although engaging CD16a is essential for the therapeutic activ-
ity of most mAbs, CD16b has emerged as an important target
(35). The recent realization that targeting CD16b may improve
these drugs is partially due to the roughly 50-fold higher
amount of CD16b in the human body compared with CD16a.
We estimate that the average person containsmore than 200g
of CD16b from neutrophils in circulation compared with just 4
g of CD16a frommonocytes and NK cells (2, 19, 47). Perhaps
because of this difference in abundance, mAbs that specifically
target CD16b provide definite advantages. One glycoengi-
neered anti-CD20 antibody, obinutuzumab, showed greater
therapeutic efficacy than the standard anti-CD20 therapy ritux-
imab because of higher affinity and an ability to activate neu-
trophils through CD16b but not CD32a (35). Another study
also found that glycoengineered nonfucosylated rituximab sim-
ilarly enhanced neutrophil activation through CD16b engage-
ment (36). These findings demonstrate that increasing the
CD16b binding affinity of mAbs provides better therapeutic
responses and potentially lower doses in the clinic. Our finding
that Asp-129 substantially decreases rCD16b affinity for IgG1
Fc indicates that designing antibodies to accommodate the
Asp-129 side chain may improve CD16b binding affinity and
contribute to improved therapeutic outcomes.
Experimental procedures
Materials
All materials were purchased from Sigma-Aldrich unless
noted otherwise.
Protein expression and purification
CD16a (V158) and CD16b (NA2) were previously cloned
into the Not1 and EcoR1 restriction sites of the pGen2 vector
(5, 48, 49). CD16a and CD16b cloned into a pUC57 vector
served as templates to generate genes encodingmutated recep-
tors according to the QuikChange protocol (Agilent). Muta-
tions were verified by DNA sequencing at the Iowa State Uni-
versity DNA facility. Verified mutant genes were subcloned
into the pGen2 plasmid using the Not1 and EcoR1 restriction
enzymes (49).
Expression and purification of CD16 with complex-type
N-glycans was achieved by expression fromHEK293F cells and
purification as described previously (5). CD16 with oligoman-
nose (Man5) N-glycans was expressed using the HEK293S cell
line as described previously (19). Typical yields were 0.2
mg/ml of final culture volume. IgG1 Fc used for binding analy-
ses and single IgG1 Fc glycoforms were prepared as described
previously (5). Binding analyses for the previous report (5) and
the results reported in this manuscript were collected within a
few days of one another. IgG1 Fc lacking a fucose residue was
used for crystallography and was prepared by expressing pro-
tein in the presence of 250 M 2-fluoro-2-deoxy fucose as
described previously (5). Glycomics analyses of PNGaseF-re-
leased N-glycans using HILIC-ESI-MS/MS were performed as
described previously (19).
Crystallization of the CD16b–IgG1 Fc complex
CD16b-N38Q/N64Q/N74Q/N169Q with Man5 N-glycans
was transferred to a buffer containing 50 mM Tris, 100 mM
sodiumchloride, and 0.5mMEDTA (pH8.0). A 1:50molar ratio
(receptor:tobacco etch virus–GFP) was added, and the samples
were incubated overnight in the dark at room temperature.
CD16 was separated fromGFP by flowing over a nickel-nitrilo-
triacetic acid resin (Qiagen) and concentrating the flow-
through fractions containing CD16. CD16 was exchanged into
a buffer containing 20 mMMOPS and 100 mM sodium chloride
(pH 7.2) with an Amicon Ultra centrifugal filter with a 10-kDa
molecular weight cutoff (Merck Millipore). CD16 was then
mixed with IgG1 Fc (-fucose) at a (1:1.5) molar ratio. Complex
was separated from unbound IgG1 Fc by purification with an
AKTAPure chromatography system equippedwith a Superdex
200 gel filtration column pre-equilibrated with a buffer con-
taining 20 mM MOPS and 100 mM sodium chloride (pH 7.2)
(GE Healthcare Bio-Sciences). Fractions containing the
CD16–Fc complex were identified by SDS-PAGE and concen-
trated to 12 mg/ml. Crystals in the P212121 space group were
obtained using the hanging dropmethodwith a well solution of
50 mM MES, 10% PEG3350 (w/v), and 50 mM sodium chloride
(pH6.0). Crystals in theC2 space groupwere obtained using the
hanging drop method with a well solution of 50 mM MES, 8%
PEG3350 (w/v), and 60 mM sodium chloride. All crystals were
cryoprotected with 15% ethylene glycol diluted with well solu-
tion and flash-frozen in liquid nitrogen. Diffraction data were
collected at 1° increments for 200 frames with an exposure time
of 0.5 s on beamline 23-ID-D at the Argonne National Labora-
toryAdvanced Photon Sourcewith a Pilatus3 6Mdetector. The
software HKL-3000 was used to index, scale, and merge data-
sets. Initial phases were determined with molecular replace-
ments in Phenix-Phaser MR using PDB code 5VU0 (20). Final
refinement was performed with Phenix using secondary struc-
ture restraints and noncrystallographic symmetry restraints.
The structure was deposited in the PDB as 6EAQ. Measure-
ments of interfaces and buried surface area were made using
the PDBePISA utility (45). Molecular dynamics simulations of
CD16b Asp-129 decreases affinity for IgG1
19906 J. Biol. Chem. (2018) 293(51) 19899–19908
 at IO
W
A
 STA
TE U
N
IV
 on February 18, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the glycosylated CD16b–Fc complex were performed using
Amber16 as described previously (20).
Surface plasmon resonance binding experiments
Binding experiments were performed as described previ-
ously (5). For interactions that reached a clear equilibrium, the
intensity values of the association phasewere fittedwith a bind-
ing isotherm to determine a dissociation constant for the inter-
action. For slower interactions where a clear equilibrium was
not achieved, dissociation constants were calculated using the
observed on and off rates as described previously (5). Values for
Tables 1 and 2 include errors resulting from the least-squares
fitting procedure.
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